(Q33346855)

26 July 2017

1 reference

title

Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy (English)

1 reference

heparin-induced thrombocytopenia

26 July 2017

1 reference

1 reference

1 reference

Jeanine M Walenga

1

1 reference

26 July 2017

Eugene P Frenkel

series ordinal

2

1 reference

26 July 2017

Rodger L Bick

series ordinal

3

1 reference

26 July 2017

language of work or name

1 reference

1 February 2003

1 reference

Hematology / Oncology Clinics of North America

26 July 2017

published in

1 reference

26 July 2017

volume

17

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

259-82, viii-ix

1 reference

Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Delayed-onset heparin-induced thrombocytopenia and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Temporal aspects of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Elevated Plasma Vascular Endothelial Cell Growth Factor and Thrombomodulin in Juvenile Diabetic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Pregnancy complicated by heparin associated thrombocytopenia: Management by a prospectively in vitro selected heparinoid (ORG 10172)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin‐induced thrombocytopenia: an improved method of detection based on lumi‐aggregometry

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

A 14-year study of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Arterial Embolism Occurring During Systemic Heparin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin-induced thrombocytopenia and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Immune endothelial-cell injury in heparin-associated thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Use of low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombotic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Diagnosis of heparin-induced thrombocytopenia. Still a journey, not yet a destination

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Critical ischemia during heparin-induced thrombocytopenia. Treatment by intra-arterial streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Intraoperative management of patients with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin-induced cutaneous necrosis unrelated to injection sites. A sign of potentially lethal complications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin doses and major bleedings

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Management of heparin therapy: Controlled prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

The Hazards of Aspirin plus Heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

MULTIPLE FRACTURES ASSOCIATED WITH LONG-TERM SODIUM HEPARIN THERAPY

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Nonhemorrhagic complications of anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin fails to potentiate the effects of IL-1 beta-mediated bone resorption of fetal rat long bones in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin-induced skin lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin necrosis. An anticoagulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Hemorrhagic complications of anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Thrombotic complications of heparin therapy: including six cases of heparin--induced skin necrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin-induced hypoaldosteronism. Report of a case

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Thrombocytopenia associated with low-molecular-weight heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900088-6

7 January 2021

10.1016/S0889-8588(02)00088-6

Identifiers

DOI

1 reference

26 July 2017

1 reference